BLISSGVS
Bliss GVS Pharma share price & financials
- Price
- ₹486.3
- Market cap
- ₹7.6k Cr
- Sector
- Healthcare
What Bliss GVS Pharma Limited does
Bliss GVS Pharma, incorporated in 1984 and headquartered in Mumbai, manufactures and markets branded pharmaceutical formulations with a global leadership position in the suppositories and pessaries dosage forms. It runs eight manufacturing units across Maharashtra (Palghar, Ambernath, Vevoor) and Nigeria, producing tablets, suppositories/pessaries, capsules, ointments/creams/gels, sachets, dry syrups, lozenges and skincare products across therapeutic categories such as anti-malarial, anti-fungal, anti-inflammatory, anti-biotic and laxative. It earns primarily through branded exports concentrated in Sub-Saharan Africa (brands such as Lonart, Funbact, P-Alaxin, Lofnac and Gsunate) alongside in-licensed suppository manufacturing for global pharma majors including Sanofi, Alkem, Sun Pharma, Mankind, Neon and Intas.
Segments
- Suppositories & Pessaries
- Other Pharmaceutical Formulations
- Market position
- World leader in suppositories & pessaries dosage forms, with one of the largest product portfolios in this segment globally
- Manufacturing facilities
- 8 units — 6 in Maharashtra (Palghar, Ambernath, Vevoor) and 2 in Nigeria (Nigeria units to be divested in FY26)
- Countries present
- 60+
- Brands
- 150+
- Products manufactured
- 400+
- Therapeutic segments
- 50+
Quarterly results
Q1 FY27: revenue up 38.2%, net profit up 15.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 218 | 210 | 198 | 207 | 244 +12% | 218 +4% | 257 +30% | 286 +38% |
| EBITDA | 41 | 30 | 21 | 41 | 43 +5% | 35 +17% | 44 +110% | 76 +85% |
| Net profit | 26 | 26 | 17 | 44 | 29 +12% | 25 −4% | 37 +118% | 51 +16% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +372.1% 1Y
1Y: ₹152.7 on 10 Sept 2025 → ₹720.95. High ₹722.3 (8 Sept 2026), low ₹127.9 (7 Nov 2025).
Financials, as filed
Revenue grew 7.2% a year over 3 years, FY23 to FY26. Operating margin widened to 17.6%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹752 Cr | ₹771 Cr | ₹810 Cr | ₹926 Cr |
| Operating profit | ₹118 Cr | ₹150 Cr | ₹126 Cr | ₹163 Cr |
| Operating margin | 15.7% | 19.5% | 15.6% | 17.6% |
| Interest | ₹10 Cr | ₹6 Cr | ₹9 Cr | ₹11 Cr |
| Depreciation | ₹20 Cr | ₹26 Cr | ₹30 Cr | ₹33 Cr |
| Net profit | ₹76 Cr | ₹81 Cr | ₹91 Cr | ₹135 Cr |
| Net margin | 10.1% | 10.5% | 11.2% | 14.6% |
| Cash from operations | ₹34 Cr | ₹103 Cr | ₹106 Cr | ₹139 Cr |
| Free cash flow | ₹-59 Cr | ₹75 Cr | ₹33 Cr | ₹84 Cr |
| ROCE | 12.0% | 14.0% | 12.0% | 17.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹10 Cr | ₹11 Cr | ₹11 Cr |
| Reserves | ₹798 Cr | ₹808 Cr | ₹873 Cr | ₹957 Cr | ₹1.1k Cr | ₹1.2k Cr |
| Borrowings | ₹122 Cr | ₹109 Cr | ₹102 Cr | ₹100 Cr | ₹52 Cr | ₹22 Cr |
| Other liabilities | ₹147 Cr | ₹181 Cr | ₹171 Cr | ₹145 Cr | ₹215 Cr | ₹278 Cr |
| Total liabilities | ₹1.1k Cr | ₹1.1k Cr | ₹1.2k Cr | ₹1.2k Cr | ₹1.4k Cr | ₹1.5k Cr |
| Fixed assets | ₹234 Cr | ₹281 Cr | ₹379 Cr | ₹370 Cr | ₹392 Cr | ₹459 Cr |
| Capital work in progress | ₹2 Cr | ₹22 Cr | ₹3 Cr | ₹8 Cr | ₹39 Cr | ₹6 Cr |
| Investments | ₹0 Cr | ₹2 Cr | ₹8 Cr | ₹4 Cr | ₹10 Cr | ₹5 Cr |
| Other assets | ₹840 Cr | ₹803 Cr | ₹768 Cr | ₹830 Cr | ₹959 Cr | ₹1.0k Cr |
| Total assets | ₹1.1k Cr | ₹1.1k Cr | ₹1.2k Cr | ₹1.2k Cr | ₹1.4k Cr | ₹1.5k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, FIIs trimmed −4.58 pp while DIIs added +2.92 pp.
- Promoters
- 35.0%
- FIIs
- 8.1%
- DIIs
- 9.5%
- Public
- 47.5%
Since Jun 2025
- FIIs −4.58 pp
- DIIs +2.92 pp
- Public +2.08 pp
How it drifted, 12 quarters
Over this window FIIs fell from 16.3% to 8.1% — −8.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 35.1%, FIIs 16.3%, DIIs 6.6%, Public 42.0%.Dec '23: Promoters 35.0%, FIIs 15.3%, DIIs 6.6%, Public 43.1%.Mar '24: Promoters 35.0%, FIIs 14.7%, DIIs 6.6%, Public 43.7%.Jun '24: Promoters 34.9%, FIIs 13.2%, DIIs 6.6%, Public 45.3%.Sep '24: Promoters 34.8%, FIIs 12.1%, DIIs 6.6%, Public 46.5%.Dec '24: Promoters 35.1%, FIIs 13.5%, DIIs 6.5%, Public 44.8%.Mar '25: Promoters 35.3%, FIIs 13.2%, DIIs 6.5%, Public 45.0%.Jun '25: Promoters 35.4%, FIIs 12.7%, DIIs 6.5%, Public 45.4%.Sep '25: Promoters 35.4%, FIIs 13.3%, DIIs 6.0%, Public 45.4%.Dec '25: Promoters 35.4%, FIIs 14.5%, DIIs 5.8%, Public 44.3%.Mar '26: Promoters 35.4%, FIIs 10.4%, DIIs 5.0%, Public 49.1%.Jun '26: Promoters 35.0%, FIIs 8.1%, DIIs 9.5%, Public 47.5%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Clarus Capital I VC / PE newly disclosed 3.51% held
- 360 One Pipe Fund Mutual fund newly disclosed 1.16% held
- Mateus Ltd FPI fund newly disclosed 1.08% held
The same filing shows 4 holders trimming and 3 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Bliss GVS Pharma Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Narsimha Shibroor Kamath | 30.58% | −0.08 pp |
| Gulbarga Trading And Investment Private | 5.50% | unchanged |
| Arjun Gautam Ashra . | 4.76% | unchanged |
| Clarus Capital I VC / PE | 3.51% | newly disclosed |
| Life Insurance Corporation Of India Insurer | 3.24% | −1.09 pp |
| Gautam Rasiklal Ashra | 2.81% | unchanged |
| Investor Education And Protection Fund Authority Ministry Of Corporate Affairs | 2.48% | unchanged |
| Vibha Gagan Sharma | 2.43% | unchanged |
| Shruti Vishal Rao | 1.99% | unchanged |
| Coeus Global Opportunities Fund FPI fund | 1.75% | unchanged |
| Arian Investment Limited Unclassified | 1.36% | −1.09 pp |
| 360 One Pipe Fund Mutual fund | 1.16% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
Growth trapTo justify its price of ₹721, this stock must grow earnings at 36% every year for 7 years. Our analysis caps realistic growth at ~12%. At that growth it is worth ₹220 — downside of 70%.
- Growth the price implies
- 35.8% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 12.1% a year
- net profit, FY23–FY26 · EPS 12.2%
- The gap
- 0.2 pp
- -70% downside if it only repeats history
Learn to analyse Bliss GVS Pharma Limited
Guides on how to read this kind of business and the numbers that matter.